The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease

References

• D’Souza AZX Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. [cited 2017 Oct 10].  Available from: http://www.cibmtr.org (2016).
   Google Scholar
• Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565–2579.
   PubMed Web of Science ®Google Scholar
• Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012;18(1):S116–S124.
   PubMed Web of Science ®Google Scholar
• Paczesny S, Raiker N, Brooks S, et al. Graft-versus-host disease biomarkers: omics and personalized medicine. Int J Hematol. 2013;98(3):275–292.
   PubMed Web of Science ®Google Scholar
• MacDonald KPA, Hill GR, Blazar BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood. 2017;129(1):13–21.
   PubMed Web of Science ®Google Scholar
• Paczesny S, Hakim FT, Pidala J, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015;21(5):780–792.
   PubMed Web of Science ®Google Scholar
• Wolff D, Greinix H, Lee SJ, et al. Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplant. 2018;24(10):018–0092.
   Google Scholar
• Paczesny S. Graft-versus-host disease in children after hematopoietic cell transplantation: potential clinical utility of biomarkers. Int J Hematol Oncol. 2015;4(2):51–54.
   Google Scholar
• Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transpl. 2006;12(2):126–137.
   PubMed Web of Science ®Google Scholar
• Hu ZZ, Huang H, Wu CH, et al. Omics-based molecular target and biomarker identification. Methods Mol Biol. 2011;719:547–571.
   PubMedGoogle Scholar
• Bogunia-Kubik K, Mizia S, Gronkowska A, et al. CCR5 gene polymorphism affects the risk of GvHD after haematopoietic stem cell transplantation from an unrelated donor. Br. J. Haematol. 2015. doi: 10.1111/bjh.13387. [Epub ahead of print]
   PubMedGoogle Scholar
• Karaesmen E, Rizvi AA, Preus L, et al. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood. 2017;130:1585–1596.
   PubMed Web of Science ®Google Scholar
• Lowe R, Shirley N, Bleackley M, et al. Transcriptomics technologies. PLoS Comput Biol. 2017;13(5):e1005457.
   PubMed Web of Science ®Google Scholar
• Tomuleasa C, Fuji S, Cucuianu A, et al. MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. Ann Hematol. 2015;94(7):1081–1092.
   PubMed Web of Science ®Google Scholar
• Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2011;118(21):SCI-50–SCI-50.
   Web of Science ®Google Scholar
• Jin X-F, Wu N, Wang L, et al. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol. 2013;33(5):601–613.
   PubMed Web of Science ®Google Scholar
• Xie LN, Zhou F, Liu XM, et al. Serum microRNA155 is increased in patients with acute graft-versus-host disease. Clin Transplant. 2014;28(3):314–323.
   PubMed Web of Science ®Google Scholar
• Garchow B, Kiriakidou M. MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus. Clin Immunol. 2016;162:100–106.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Ngankeu A, Zitzer NC, et al. Serum miR-29a is upregulated in acute graft-versus-host disease and activates dendritic cells through TLR binding. J Immunology. 2017;198(6):2500–2512.
   PubMed Web of Science ®Google Scholar
• Furlan SN, Watkins B, Tkachev V, et al. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med. 2015;7(315):315ra191.
   PubMed Web of Science ®Google Scholar
• Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013;121(4):585–594.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang J, Li J, et al. Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol Cell Proteomics. 2016;15(2):614–623.
   PubMed Web of Science ®Google Scholar
• Kitko CL, Levine JE, Storer BE, et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 2014;123(5):786–793.
   PubMed Web of Science ®Google Scholar
• Anjo SI, Santa C, Manadas B, et al. SWATH-MS as a tool for biomarker discovery: from basic research to clinical applications. Proteomics. 2017;17:3–4.
   Web of Science ®Google Scholar
• Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation–quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8(4):840–858.
   PubMed Web of Science ®Google Scholar
• Crutchfield CA, Thomas SN, Sokoll LJ, et al. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics. 2016;13:1.
   PubMed Web of Science ®Google Scholar
• Savaryn JP, Toby TK, Kelleher NL. A researcher’s guide to mass spectrometry-based proteomics. Proteomics. 2016;16(18):2435–2443.
   PubMed Web of Science ®Google Scholar
• Matos TR, Liu H, Ritz J. Research techniques made simple: mass cytometry analysis tools for decrypting the complexity of biological systems. J Invest Dermatol. 2017;137(5):e43–e51.
   PubMed Web of Science ®Google Scholar
• Kay AW, Strauss-Albee DM, Blish CA. Application of mass cytometry (cytof) for functional and phenotypic analysis of natural killer cells. Methods Mol Biol. 2016;1441:13–26.
   PubMedGoogle Scholar
• Ornatsky O, Bandura D, Baranov V, et al. Highly multiparametric analysis by mass cytometry. J Immunol Methods. 2010;361(1–20):(1–2).
   PubMed Web of Science ®Google Scholar
• Paczesny S, Hakim FT, Pidala J, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015;21:780–792.
   PubMed Web of Science ®Google Scholar
• O’Connor JP, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017;14(3):169–186.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Li CI, Feng Z. Improving the quality of biomarker discovery research: the right samples and enough of them. Cancer Epidemiology, Biomarkers Prevention: Publication American Association Cancer Research, Cosponsored by American Society Preventive Oncology. 2015;24(6):944–950.
   Google Scholar
• Pepe M, Longton G, Janes H. Estimation and comparison of receiver operating characteristic curves. Stata J. 2009;9(1):1.
   PubMed Web of Science ®Google Scholar
• Xia J, Broadhurst DI, Wilson M, et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics: Official Journal of the Metabolomic Society. 2013;9(2):280–299.
   PubMed Web of Science ®Google Scholar
• Ensor JE. Biomarker validation: common data analysis concerns. Oncologist. 2014;19(8):886–891.
   PubMed Web of Science ®Google Scholar
• Van Calster B, Vickers AJ, Pencina MJ, et al. Evaluation of markers and risk prediction models: overview of relationships between NRI and decision-analytic measures. Medical Decision Making: an International Journal of the Society for Medical Decision Making. 2013;33(4):490–501.
   PubMed Web of Science ®Google Scholar
• Weissinger EM, Human C, Metzger J, et al. The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation. Leukemia. 2017;31(3):654–662.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007;13(20):6107–6114.
   PubMed Web of Science ®Google Scholar
• Fujii H, Cuvelier G, She K, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s Oncology Group. Blood. 2008;111(6):3276–3285.
   PubMed Web of Science ®Google Scholar
• Kariminia A, Holtan SG, Ivison S, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: the only consistent association is with CXCL10 and CXCR3+ NK cells. Blood. 2016;127(24):3082–3091.
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Wang XN, Norden J, et al. Identification and validation of biomarkers associated with acute and chronic graft versus host disease. Bone Marrow Transplant. 2015;50(12):1563–1571.
   PubMed Web of Science ®Google Scholar
• Saliba RM, Sarantopoulos S, Kitko CL, et al. B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality. Bone Marrow Transplant. 2017;52:1010–1015.
   PubMed Web of Science ®Google Scholar
• Liem L, Van Houwelingen H, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation. 1998;66(7):863–871.
   PubMed Web of Science ®Google Scholar
• Yu J, Storer BE, Kushekhar K, et al. Biomarker panel for chronic graft-versus-host disease. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2016;34(22):2583–2590.
   PubMed Web of Science ®Google Scholar
• Hakim FT, Memon S, Jin P, et al. Upregulation of IFN-inducible and damage-response pathways in chronic graft-versus-host disease. J Immunol. 2016;197(9):3490–3503.
   PubMed Web of Science ®Google Scholar
• Abu Zaid M, Wu J, Wu C, et al. Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017;129(2):162–170.
   PubMed Web of Science ®Google Scholar
• Croudace JE, Inman CF, Abbotts BE, et al. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 2012;120(20):4246–4255.
   PubMed Web of Science ®Google Scholar
• Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475. doi: 10.3389/fimmu.2017.00475. eCollection 2017.
   PubMedGoogle Scholar
• O’Sullivan S, Gilmer JF, Medina C. Matrix metalloproteinases in inflammatory bowel disease: an update. Mediators Inflamm. 2015;2015:964131. doi: 10.1155/2015/964131.
   PubMedGoogle Scholar
• Liu X, Yue Z, Yu J, et al. Proteomic characterization reveals that MMP-3 correlates with bronchiolitis obliterans syndrome following allogeneic hematopoietic cell and lung transplantation. Am Journal Transplantation: Official Journal Am Soc Transplant Am Soc Transpl Surgeons. 2016;16:2342–2351.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Martin PJ, Paczesny S, et al. Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(8):1250–1256.
   PubMed Web of Science ®Google Scholar
• Rice LM, Mantero JC, Stifano G, et al. A proteome-derived longitudinal pharmacodynamic biomarker for diffuse systemic sclerosis skin. J Invest Dermatol. 2017;137(1):62–70.
   PubMed Web of Science ®Google Scholar
• Du J, Flynn R, Paz K, et al. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood. 2018;131(15):1636–1743.
   Web of Science ®Google Scholar
• Pidala J, Sigdel TK, Wang A, et al. A combined biomarker and clinical panel for chronic graft versus host disease diagnosis. J Pathol Clin Res. 2017;3(1):3–16.
   PubMedGoogle Scholar
• Holtan SG, Khera N, Levine JE, et al. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016;128(19):2350–2358.
   PubMed Web of Science ®Google Scholar
• She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2007;13(4):386–397.
   PubMed Web of Science ®Google Scholar
• Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14(2):208–219.
   PubMed Web of Science ®Google Scholar
• Kuzmina Z, Krenn K, Petkov V, et al. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886–1895.
   PubMed Web of Science ®Google Scholar
• D’Orsogna LJ, Wright MP, Krueger RG, et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol Blood Marrow Transplant. 2009;15(7):795–803.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113(16):3865–3874.
   PubMed Web of Science ®Google Scholar
• Dander E, Balduzzi A, Zappa G, et al. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation. 2009;88(11):1261–1272.
   PubMed Web of Science ®Google Scholar
• Zhao XY, Lv M, Xu LL, et al. Donor Th17 cells and IL-21 may contribute to the development of chronic graft-versus-host disease after allogeneic transplantation. Eur J Immunol. 2013;43(3):838–850.
   PubMed Web of Science ®Google Scholar
• Malard F, Bossard C, Brissot E, et al. Increased Th17/Treg ratio in chronic liver GVHD. Bone Marrow Transplant. 2014;49(4):539–544.
   PubMed Web of Science ®Google Scholar
• Forcade E, Paz K, Flynn R, et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017;2(12). pii: 92111. doi: 10.1172/jci.insight.92111. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Greinix HT, Kuzmina Z, Weigl R, et al. CD19+CD21low B cells and CD4+CD45RA+CD31+ T cells correlate with first diagnosis of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(2):250–258.
   PubMed Web of Science ®Google Scholar
• Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903–2911.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120(5):1479–1493.
   Web of Science ®Google Scholar
• Clark FJ, Gregg R, Piper K, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood. 2004;103(6):2410–2416.
   PubMed Web of Science ®Google Scholar
• Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5):646–657.
   PubMed Web of Science ®Google Scholar
• Forcade E, Kim HT, Cutler C, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016;127(20):2489–2497.
   PubMed Web of Science ®Google Scholar
• Hirakawa M, Matos TR, Liu H, et al. Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016;1(18):e89278.
   PubMed Web of Science ®Google Scholar
• Huenecke S, Cappel C, Esser R, et al. Development of three different NK cell subpopulations during immune reconstitution after pediatric allogeneic hematopoietic stem cell transplantation: prognostic markers in GVHD and viral infections. Front Immunol. 2017;8:109.
   PubMed Web of Science ®Google Scholar
• Kariminia A, Ivison S, Ng B, et al. CD56(bright) natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Haematologica. 2017;102(11):1936–1946.
   PubMed Web of Science ®Google Scholar
• Skert C, Damiani D, Michelutti A, et al. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. Bone Marrow Transplant. 2009;44(11):729–737.
   PubMed Web of Science ®Google Scholar
• Stikvoort A, Chen Y, Radestad E, et al. Combining flow and mass cytometry in the search for biomarkers in chronic graft-versus-host disease. Front Immunol. 2017;8:717. doi: 10.3389/fimmu.2017.00717. eCollection 2017.
   PubMed Web of Science ®Google Scholar
• Botari CME, Nunes AJF, De Souza MP, et al. Oral chronic graft-versus-host disease: analysis of dendritic cells subpopulations. An Bras Dermatol. 2014;89(4):632–637.
   PubMed Web of Science ®Google Scholar
• Waller EK, Rosenthal H, Sagar L. DC2 effect on survival following allogeneic bone marrow transplantation. Oncology (Williston Park). 2002;16(1 Suppl 1):19–26.
   PubMed Web of Science ®Google Scholar
• Chan GW, Gorgun G, Miller KB, et al. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(3):170–176.
   PubMed Web of Science ®Google Scholar
• Arpinati M, Chirumbolo G, Marzocchi G, et al. Increased donor CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-host disease. Transplantation. 2008;85(12):1826–1832.
   PubMed Web of Science ®Google Scholar
• Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res. 2010;16(13):3299–3318.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014;124(11):4867–4876.
   PubMed Web of Science ®Google Scholar
• Schutt SD, Fu J, Nguyen H, et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PloS One. 2015;10(9):e0137641.
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243–2250.
   PubMed Web of Science ®Google Scholar
• Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123(25):3988–3998.
   PubMed Web of Science ®Google Scholar
• Allen JL, Tata PV, Fore MS, et al. Increased BCR responsiveness in B cells from patients with chronic GVHD. Blood. 2014;123(13):2108–2115.
   PubMed Web of Science ®Google Scholar
• Leonhardt F, Zirlik K, Buchner M, et al. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia. 2012;26(7):1617–1629.
   PubMed Web of Science ®Google Scholar
• Le Huu D, Kimura H, Date M, et al. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. J Dermatol Sci. 2014;74(3):214–221.
   PubMed Web of Science ®Google Scholar
• Flynn R, Allen JL, Luznik L, et al. Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015;125(26):4085–4094.
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, et al. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114(24):4919–4927.
   PubMed Web of Science ®Google Scholar
• Teshima T. JAK inhibitors: a home run for GVHD patients? Blood. 2014;123(24):3691–3693.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–2068.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Kim HT, Bindra B, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(11):1737–1743.
   PubMed Web of Science ®Google Scholar
• Pai CC, Chen M, Mirsoian A, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014;124(10):1677–1688.
   PubMed Web of Science ®Google Scholar
• Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the Sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016;8:2.
   Web of Science ®Google Scholar
• Zerr P, Palumbo-Zerr K, Distler A, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood. 2012;120(14):2909–2917.
   PubMed Web of Science ®Google Scholar
• Furlan SN, Watkins BK, Mortari A, et al. Defining the primate t cell transcriptome during GVHD: new data implicating Sonic hedgehog and aurora kinase pathways in GVHD pathogenesis and prevention. Biol Blood Marrow Transplant. 2015;21(2):S56.
   Web of Science ®Google Scholar
• DeFilipp Z, Nazarian RM, El-Jawahri A, et al. Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Advances. 2017;1(22):1919–1922.
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–190.
   PubMed Web of Science ®Google Scholar
• Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17(11):1322–1333.
   PubMed Web of Science ®Google Scholar
• Beres AJ, Drobyski WR. The role of regulatory T cells in the biology of graft versus host disease. Front Immunol. 2013;4:163.
   PubMed Web of Science ®Google Scholar
• Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055–2066.
   PubMed Web of Science ®Google Scholar
• Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128(1):130–137.
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra143.
   Web of Science ®Google Scholar
• Kuna P, Jenkins M, O’Brien CD, et al. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir Med. 2012;106(4):531–539.
   PubMed Web of Science ®Google Scholar
• Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med. 2013;107(4):524–533.
   PubMed Web of Science ®Google Scholar
• Elborn JS, Perrett J, Forsman-Semb K, et al. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J. 2012;40(4):969–976.
   PubMed Web of Science ®Google Scholar
• Im A, Hakim FT, Pavletic SZ. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2017;31(3):543–554.
   PubMed Web of Science ®Google Scholar
• Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144–2154.
   PubMed Web of Science ®Google Scholar